Whilst it can be hard to dose, unlike alcohol’s long-lasting, blanket effects on your brain, ketamine is transient and ...

The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.

Medicaid in Wisconsin has expanded to cover ketamine infusions as of Jan. 1, sparking conversations about the nuances in type ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

so they don’t want to be on concurrent antidepressants.” Spravato is a form of esketamine that patients take as a self-administered nasal spray under the supervision of a healthcare provider.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...